Relypsa (United States)

Alternate names: Relypsa, Relypsa, Inc.

Parent institution: Vifor Pharma (Switzerland)

ROR: 05japc090

OpenAlex ID: I4405282247

Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors

2014 · Matthew R. Weir, George L. Bakris, et al. · New England Journal of Medicine · 688

Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial

2015 · George L. Bakris, Bertram Pitt, et al. · JAMA · 448

Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial

2011 · B. Pitt, S. D. Anker, et al. · European Heart Journal · 442

PDF

Association of Serum Potassium with All-Cause Mortality in Patients with and without Heart Failure, Chronic Kidney Disease, and/or Diabetes

2017 · Allan J. Collins, Bertram Pitt, et al. · American Journal of Nephrology · 421

Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial

2019 · Rajiv Agarwal, Patrick Rossignol, et al. · The Lancet · 391

PDF

Effect of Patiromer on Reducing Serum Potassium and Preventing Recurrent Hyperkalaemia in Patients with Heart Failure and Chronic Kidney Disease on Raas Inhibitors

2015 · Bertram Pitt, George L. Bakris, et al. · European Journal of Heart Failure · 162

PDF

Calcium Balance in Chronic Kidney Disease

2017 · Kathleen M. Hill Gallant, David M. Spiegel · Current Osteoporosis Reports · 126

PDF

Mechanism of Action and Pharmacology of Patiromer, a Nonabsorbed Cross-Linked Polymer That Lowers Serum Potassium Concentration in Patients With Hyperkalemia

2016 · Lingyun Li, Stephen D. Harrison, et al. · Journal of Cardiovascular Pharmacology and Therapeutics · 114

PDF

Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia

2015 · David A. Bushinsky, Gordon H. Williams, et al. · Kidney International · 113

PDF

Serum Potassium and Short-term Clinical Outcomes Among Hemodialysis Patients: Impact of the Long Interdialytic Interval

2017 · Steven M. Brunelli, Charles Du Mond, et al. · American Journal of Kidney Diseases · 95

Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors

2016 · Matthew R. Weir, George L. Bakris, et al. · Kidney International · 65

PEARL-HF: Prevention of Hyperkalemia in Patients With Heart Failure Using a Novel Polymeric Potassium binder, RLY5016

2011 · Jerry M Buysse, I-Zu Huang, et al. · Future Cardiology · 60

Evaluation of an Individualized Dose Titration Regimen of Patiromer to Prevent Hyperkalaemia in Patients with Heart Failure and Chronic Kidney Disease

2018 · Bertram Pitt, David A. Bushinsky, et al. · ESC Heart Failure · 58

PDF

Long-Term Effects of Patiromer for Hyperkalaemia Treatment in Patients with Mild Heart Failure and Diabetic Nephropathy on Angiotensin-Converting Enzymes/Angiotensin Receptor Blockers: Results from AMETHYST-DN

2018 · Bertram Pitt, George L. Bakris, et al. · ESC Heart Failure · 57

PDF

Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints

2017 · Patrick Rossignol, Rajiv Agarwal, et al. · European Heart Journal · 57

PDF

The phospholipase A2 inhibitor methyl indoxam suppresses diet‐induced obesity and glucose intolerance in mice

2009 · DY Hui, MJ Cope, et al. · British Journal of Pharmacology · 56

Patiromer Versus Placebo to Enable Spironolactone Use in Patients with Resistant Hypertension and Chronic Kidney Disease ( AMBER ): Results in the Pre-Specified Subgroup with Heart Failure

2020 · Patrick Rossignol, Bryan Williams, et al. · European Journal of Heart Failure · 55

PDF

Serum-to-dialysate potassium gradient and its association with short-term outcomes in hemodialysis patients

2017 · Steven M Brunelli, David M Spiegel, et al. · Nephrology Dialysis Transplantation · 54

The evaluation and management of drug effects on cardiac conduction (PR and QRS Intervals) in clinical development

2013 · Adel Nada, Gary A. Gintant, et al. · American Heart Journal · 54

Patiromer Decreases Serum Potassium and Phosphate Levels in Patients on Hemodialysis

2016 · David A. Bushinsky, Patrick Rossignol, et al. · American Journal of Nephrology · 53

PDF

Real-World Evaluation of Patiromer for the Treatment of Hyperkalemia in Hemodialysis Patients

2018 · Csaba P. Kovesdy, Christopher G. Rowan, et al. · Kidney International Reports · 52

PDF

Clinical and Economic Impact of Hyperkalemia in Patients with Chronic Kidney Disease and Heart Failure

2017 · Michael Polson, Todd C. Lord, et al. · Journal of Managed Care & Specialty Pharmacy · 51

PDF

Effect of Patiromer on Urinary Ion Excretion in Healthy Adults

2016 · David A. Bushinsky, David M. Spiegel, et al. · Clinical Journal of the American Society of Nephrology · 51

Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors

2017 · Matthew R. Weir, David A. Bushinsky, et al. · The American Journal of Medicine · 45

PDF

The risk of medically uncontrolled secondary hyperparathyroidism depends on parathyroid hormone levels at haemodialysis initiation

2020 · Nahid Tabibzadeh, Angelo Karaboyas, et al. · Nephrology Dialysis Transplantation · 42

PDF

Works count: 98

Citation count: 15,290